TransMedics Stock: Waiting On 2027 Catalysts (NASDAQ:TMDX)
TransMedics' clinical trials are only moving forward slowly, potentially delaying a critical growth catalyst. Read why TMDX stock is upgraded to a buy.
- TransMedics: Waiting On 2027 Catalysts (Rating Upgrade) · seekingalpha.com · 2 days ago